ライフサイエンスコーパス: cancer

1 y, bacteriocins have even been used to treat cancer.

2 f obesity/diabetes, bacterial infection, and cancer.

3 sitive (ER(+ve)) breast cancer and for colon cancer.

4 lower risks of breast cancer and colorectal cancer.

5 noma (MCC), an extremely lethal form of skin cancer.

6 effects, congenital birth defects, childhood cancer.

7 a notable source of pathogenesis, including cancer.

8 ells and how that regulation is corrupted in cancer.

9 Glioblastoma is a devastating form of brain cancer.

10 nce the likelihood of conversion to cervical cancer.

11 y cause adverse outcomes among patients with cancer.

12 were diagnosed with Barrett's oesophagus or cancer.

13 strated critical roles for USP22 in prostate cancer.

14 pment of high-grade dysplasia and pancreatic cancer.

15 es, particularly in genomic studies of human cancer.

16 as one of the most distinctive signatures of cancer.

17 overtreatment and undertreatment of prostate cancer.

18 ing for patients who are unlikely to develop cancer.

19 ce, transplantation, autoimmune diseases and cancer.

20 tional pro-survival function of caspase-8 in cancer.

21 approach to combinatorial immunotherapy for cancer.

22 targeted approach to treating many types of cancer.

23 ajor challenge in treating advanced prostate cancer.

24 markers for the clinical diagnosis of breast cancer.

25 ciated with lower odds of epithelial ovarian cancer.

26 s in women with HER2-negative primary breast cancer.

27 d can go awry in various diseases, including cancer.

28 of these treatments in patients with diverse cancers.

29 strategies for these presently lethal brain cancers.

30 ption factor expressed in over 50% of breast cancers.

31 growth and metastasis in numerous Ras-driven cancers.

32 and homeostasis, and are disrupted in human cancers.

33 y volunteers and in patients with esophageal cancers.

34 mplicated in neurodegenerative disorders and cancers.

35 tient outcomes in cervical and head and neck cancers.

36 rapies in homologous recombination-deficient cancers.

37 an provide a new avenue for the treatment of cancers.

38 d for precision-targeting of a wide range of cancers.

39 Cancer and reach an average 94% for specific cancers.

40 nts, 96 VUS, and 34 LB/B variants, mostly in cancer (40%) and cardiac (27%) risk genes.

41 Cancer, a disease that is prone to drug resistance, is i

42 ated whole-genome sequencing data from 2,658 cancers across 38 tumor types, we analyzed 288,457 somat

43 atients with biochemically relapsed prostate cancer after primary local therapy.

44 up, randomised trial, patients with advanced cancer, aged at least 18 years, admitted to the palliati

45 anism of antiandrogen resistance in prostate cancer amenable to clinical testing using available targ

46 d cause of cancer-related deaths (after lung cancer) among women.

47 Here, as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of t

48 53 is the most frequently mutated protein in cancer and almost all cancers exhibit malfunction along

49 al activity levels and lower risks of breast cancer and colorectal cancer.

50 BRD9 is overexpressed in ovarian cancer and depleting BRD9 sensitizes cancer cells to ola

51 Mice bearing MDA-MB-231 breast cancer and FaDu head neck cancer xenografts show differe

52 tions for estrogen positive (ER(+ve)) breast cancer and for colon cancer.

53 18)F-FDG PET/CT images in patients with lung cancer and lymphoma.

54 and its tissue concentration is elevated in cancer and neurological disorders.

55 nsors for exosomes detection in the field of cancer and other diseases and demonstrate how nanobiosen

56 ns in furthering our understanding of JAM in cancer and provide a paradigm for exploring additional r

57 rmal samples with an accuracy of 90% for Pan-Cancer and reach an average 94% for specific cancers.

58 % of patients diagnosed with invasive breast cancer and refined OS estimates.

59 Furthermore, using PDX models of colon cancer and resected tumors from colon cancer patients, o

60 cal bidirectional association between breast cancer and schizophrenia may partly be explained by the

61 l familial aggregation of breast and ovarian cancer and were adjusted for the family-specific ascerta

62 ospective hallmarks that might apply to both cancer and wound healing and discuss how wounding, as in

63 s particularly induced in aggressive thyroid cancers and in patients who had poorer outcomes followin

64 d in several malignancies, including gastric cancer, and is an important biomarker in drug discovery.

65 ved as potential prognostic markers for lung cancer, and M2 predominance and juxtaposition of M2 TAM

66 moting metastasis of breast cancer, prostate cancer, and melanoma.

67 Breast cancer is the most common cancer, and the second cause of cancer-related deaths (a

68 dney Kimmel Center for Prostate and Urologic Cancers, and the National Institutes of Health (National

69 are effective immunotherapeutics to restore cancer- and virus-induced exhausted CD8(+) T cells, by e

70 ective cohort of women diagnosed with breast cancer at age <= 40 years and enrolled patients between

71 p Study (1986-2016) who were free of CVD and cancer at baseline.

72 mples, and phenotypic assays in personalized cancer avatars.

73 Breast cancer (BC) is one of the most prevalent cancers in wome

74 titis B, the stage of Barcelona Clinic Liver Cancer (BCLC) B and C, and the presence of cirrhosis, re

75 s gene-centric model has shaped the field of cancer biology and advanced understanding of cancer path

76 on, or function of protein-coding regions of cancer-biology related genes (gHFI) determines which and

77 priority research needs across the prostate cancer biomedical research domain, Movember conducted a

78 eliminated the association with endometrial cancer but had limited effect on other cancer types.

79 nique collagen fragment may regulate ovarian cancer, but in addition may help provide a useful new al

80 of adoptive cell transfer (ACT) therapy for cancer, but is limited by short exposure and high toxici

81 duce tumor growth and invasiveness of breast cancer by noncanonical mechanisms unrelated to the previ

82 Prostate cancer (CaP) relies on methylthioadenosine phosphorylase

83 also organized its recommendations regarding cancer care delivery around five goals: (1) promote and

84 d (5) improve patient access to high-quality cancer care via telemedicine.

85 and protect equitable access to high-quality cancer care; (2) support safe delivery of high-quality c

86 e; (2) support safe delivery of high-quality cancer care; (3) advance policies to ensure oncology pro

87 Clonal diversity is a consequence of cancer cell evolution driven by Darwinian selection.

88 modifications important to tumorigenesis and cancer cell growth, here we report a chemoproteomic anal

89 al transition (EMT) has been associated with cancer cell heterogeneity, plasticity, and metastasis.

90 emodelling of the blood vasculature, causing cancer cell hypoxia and death in distant avascular regio

91 as an important regulator of cell migration, cancer cell invasion, and vesicular content release, we

92 rriers and leveraging on several synergistic cancer cell killing mechanisms.

93 spheroids formed from two established human cancer cell lines (HCT116 and CAL27) to single and combi

94 In human breast cancer cell lines and 4T1 mouse mammary tumor cells, PD-

95 In this study, we cultured ovarian cancer cell lines in adherent and nonadherent conditions

96 ow sub-micromolar range among various tested cancer cell lines such as A2780 (0.23 muM), PC3 (0.48 mu

97 ncer, particularly because a large number of cancer cell lines with characteristic mesenchymal featur

98 DynaFit revealed that cell fitness in cancer cell lines, primary cancer cells, and fibroblasts

99 luation of their activity against five human cancer cell lines.

100 0.024 wt % of the total protein from breast cancer cell lysates.

101 nto understanding miRNA signaling underlying cancer cell metabolism and development of new strategies

102 ed between anti-CD20 antibodies and lymphoma cancer cell receptors.

103 selective if this pathway is overactive in a cancer cell relative to a nontransformed cell.

104 Furthermore, this poisoning may be cancer cell selective if this pathway is overactive in a

105 lates and validated with DNA from two breast cancer cell-lines and two patient tumour tissue samples

106 SPR-mediated knockout of FN3K in human liver cancer cells altered the abundance of redox metabolites,

107 THDF3 in controlling the interaction between cancer cells and brain microenvironment, thereby inducin

108 The epigenetic traits of cancer cells and of associated tumor microenvironment co

109 therapy due to their high overexpression on cancer cells and their ability to internalize together w

110 tment approach to deliver toxins directly to cancer cells are one of the fastest growing classes of o

111 well as cleaved caspase-3 and -PARP in colon cancer cells by downregulating RSK1 and MSK2 downstream

112 PYCR1 knockdown in MCF10A H-RAS(V12) breast cancer cells by inhibiting de novo proline biosynthesis

113 MUC1 knockdown in pancreatic cancer cells enhanced unfolded protein response (UPR) si

114 een tumor-infiltrating lymphocytes (TIL) and cancer cells for metabolic resources often renders T cel

115 rious human cancer cells, killing SW48 colon cancer cells in particular with a submicromolar half max

116 When cocultured with breast cancer cells in vitro, MCs hindered activation of cMET,

117 pression of the catalytic domain of PDE3A in cancer cells lacking PDE3A is sufficient to confer sensi

118 Yet our understanding of how cancer cells sense and convert mechanical stimuli into b

119 lsed magnetic field exposure of human breast cancer cells that express a sialic-acid rich glycocalyx

120 ovarian cancer and depleting BRD9 sensitizes cancer cells to olaparib and cisplatin.

121 t cell fitness in cancer cell lines, primary cancer cells, and fibroblasts under unhindered growth co

122 In both C. elegans and human cancer cells, ether-lipid synthesis protects against fer

123 its cytotoxic activity against various human cancer cells, killing SW48 colon cancer cells in particu

124 inct features to ER-negative DCIS.com breast cancer cells, leading to populations enriched with highl

125 For efficient and safe delivery to cancer cells, nucleic acids must generally be packaged i

126 uadruplex ligand that, when studied in human cancer cells, proved to be able to stabilize both G-quad

127 induced by femoral inoculation of Lewis lung cancer cells.

128 ferentially upregulated surface molecules on cancer cells.

129 by the low number of antigens restricted to cancer cells.

130 unit at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), with refractory agitat

131 itutes of Health (National Cancer Institute) Cancer Center Support Grant.

132 sive Cancer Network-designated comprehensive cancer center) within one metropolitan health system fro

133 amples from 415 tissues collected from three cancer centers (UM, USC, and KCCRI) were used to assess

134 mic alterations and are thus key targets for cancer chemoprevention.

135 ckpoint blockade (ICB) in melanoma and other cancers, clinical trials in breast cancer have reported

136 individualised risk tables for patients with cancer, considering age, sex, and tumour subtype.

137 t nucleotide resolution in intact colorectal cancer (CRC) cells.

138 ptions available to patients with colorectal cancer (CRC) is increasing, with a parallel rise in the

139 Colorectal cancer (CRC) tumors can be partitioned into four biologi

140 ma (OAC) is one of the most common causes of cancer deaths.

141 d alleles, and the contribution of different cancer deposits to ctDNA is largely unknown.

142 s did not differ significantly from those of cancers detected at radiologist double reading.

143 Recall rate (RR) percentage, cancer detection rate (CDR) per 1000 women screened, fal

144 hat folds many of the proteins essential for cancer development.

145 onditions, including cardiovascular disease, cancer, diabetes and chronic neurological diseases.

146 ntially providing an important biomarker for cancer diagnosis and treatment.

147 who experienced cardiovascular events after cancer diagnosis had increased risk of recurrence and ca

148 s in the accuracy of image-based AI for skin cancer diagnosis to address the effects of varied repres

149 small molecule compounds that target several cancer drivers has shown great therapeutic potential.

150 a significant risk factor for several common cancers (e.g., liver, colorectal, breast, pancreas).

151 Cancer elimination in humans can be achieved with immuno

152 tly mutated protein in cancer and almost all cancers exhibit malfunction along the p53 pathway.

153 tested immune-based approaches in childhood cancers, few have been guided by biomarkers or clinical-

154 ced a greater burden of premenopausal breast cancer for both new cases and deaths compared with highe

155 re variant tests implicated a known prostate cancer gene (HOXB13), as well as a novel candidate gene

156 environmental studies have focused on breast cancers generally, the preponderance of which occur afte

157 onal Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA), which aggregated whole-genom

158 d to large-scale cancer studies, such as The Cancer Genome Atlas (TCGA), with both RNA-Seq and array-

159 lysis with high accuracy when applied to the Cancer Genome Atlas datasets.

160 er Imaging Archive and genomic data from The Cancer Genome Atlas from 110 patients from five institut

161 omes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome At

162 enic driver genes and therapeutic targets in cancer genomes.

163 Cancers harbor many somatic mutations and germline varia

164 and other cancers, clinical trials in breast cancer have reported low responses to these therapies.

165 scores were calculated from personal/family cancer history.

166 Imaging data from The Cancer Imaging Archive and genomic data from The Cancer

167 Cancer immunotherapies enhance anti-tumor immune respons

168 y CTLA4 activity is blocked by antibodies in cancer immunotherapy and augmented by the provision of s

169 he interest in integrating nanomedicine with cancer immunotherapy to further improve clinical respons

170 ical activity with histologic types and lung cancer in ever and never smokers.

171 19% of them had a positive history of breast cancer in first- or second-degree relatives.

172 cancer (PC) is the most frequently diagnosed cancer in North American men.

173 AI system can be trained to detect and grade cancer in prostate needle biopsy samples at a ranking co

174 patients with advanced gastrointestinal (GI) cancer in SCRUM-Japan GOZILA (no.

175 ry, might positively or negatively influence cancer in the clinic.

176 ast cancer (BC) is one of the most prevalent cancers in women.

177 ed were an average age-standardised cervical cancer incidence of four or fewer cases per 100 000 wome

178 0.99; P trend = 0.04) for the proximal colon cancer incidence.

179 s, implicating them in many diseases besides cancer, including lung, renal, and neurodevelopmental di

180 and extend progression-free survival in many cancer indications.

181 the National Institutes of Health (National Cancer Institute) Cancer Center Support Grant.

182 Advancing understanding of neuron-cancer interactions will elucidate new therapeutic strat

183 nt emerging aspects of precision medicine in cancer is matching patients and treatments based on the

184 pecific regulation of tumor fibrosis in lung cancer is mediated through differential SMAD3 promoter m

185 Breast cancer is the most common cancer, and the second cause o

186 tic testing for hereditary predisposition to cancer is warranted in UM patients with strong personal

187 g has been intensively studied in colorectal cancer, it remains unclear whether activity in the tumor

188 d definitive treatment of localized prostate cancer (LPCa).

189 ical trials and it will further translate to cancer management.

190 Furthermore, a synergistic effect on breast cancer (MCF-7) and melanoma (SK-MEL-5) was proven.

191 ese miRNAs was transfected into human breast cancer MDA-MB-231 cells.

192 Thus, cancer methionine consumption is an immune evasion mecha

193 s an immune evasion mechanism, and targeting cancer methionine signalling may provide an immunotherap

194 In contrast, p190A forms harboring recurrent cancer mutations exhibit loss of function in modulating

195 new chemotherapeutic drug candidate against cancer, namely, [Ru(DIP)(2)(sq)](PF(6)) (Ru-sq) (DIP = 4

196 uss future opportunities for next-generation cancer nanomedicines.

197 uirements and challenges for next-generation cancer nanomedicines.

198 mplete small cell or neuroendocrine prostate cancer (NEPC) phenotype.

199 tment, Gleason score, National Comprehensive Cancer Network stage, PSA level, PSA doubling time, PSA

200 ademic hospital and a National Comprehensive Cancer Network-designated comprehensive cancer center) w

201 d genes are largely unknown, particularly in cancers not classically associated with homologous recom

202 1-5p isolated from human non-small cell lung cancer (NSCLC) tissue possesses 3'-terminal 2'Ome.

203 or proline catabolism in non-small cell lung cancer (NSCLC).

204 ts' receipt of initial assessments by a lung cancer nurse specialist and according to trust-level rep

205 ME) and ascites-derived spheroids in ovarian cancer (OC) facilitate tumor growth and progression, and

206 note; in particular, there was no history of cancer or predisposing factors for chronic liver disease

207 ylation patterns specific to either prostate cancer or prostate normal epithelium.

208 nfidence Interval [CI] 3.50-7.61) and kidney cancer (OR 2.50; 95% CI 1.69-3.72).

209 prior diagnosis of breast cancer, renal cell cancer, or leukemia underwent whole-body PET/CT imaging

210 ts with strong personal or family history of cancers, or both.

211 e opened avenues for incidental findings and cancer overdiagnosis.

212 ications for the study of this key GTPase in cancer, particularly because a large number of cancer ce

213 cancer biology and advanced understanding of cancer pathophysiology.

214 The major cause of death in prostate cancer patients can be attributed to metastatic spread o

215 The signature identified cancer patients prior to a clinical diagnosis and was su

216 entions for adult non-central nervous system cancer patients to manage cancer-related cognitive impai

217 Annual mortality rates among breast cancer patients were significantly greater in LMICs in S

218 infiltrating lymphocytes (TILs) for treating cancer patients with adoptive cell therapy.

219 ess, the majority of advanced-stage prostate cancer patients, including those with SPINK1-positive su

220 colon cancer and resected tumors from colon cancer patients, our data demonstrated that HT-DBP could

221 whether APE2 is differentially expressed in cancer patients.

222 Prostate cancer (PC) is the most frequently diagnosed cancer in N

223 evolutionary dynamics of treatment-resistant cancer populations.

224 atients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab,

225 A1 mutations perturb its function to dictate cancer progression and therapeutic response.

226 ion of the ER, its function, and its role in cancer progression and treatment.

227 D4(+) T cells, but not CD8(+) T cells, halts cancer progression as a result of tissue healing and rem

228 molecular function of STEAP1 and its role in cancer progression remain elusive.

229 r its role in promoting metastasis of breast cancer, prostate cancer, and melanoma.

230 Bladder cancer ranges from unaggressive and usually noninvasive

231 ral nervous system cancer patients to manage cancer-related cognitive impairment.

232 most common cancer, and the second cause of cancer-related deaths (after lung cancer) among women.

233 filgotinib suppresses HIV-1-driven aberrant cancer-related gene expression at the integration site.

234 for cell survival and apoptosis signaling in cancer remain to be elucidated.

235 Endometrial cancer remains the most common gynecological malignancy

236 ve patients with a prior diagnosis of breast cancer, renal cell cancer, or leukemia underwent whole-b

237 sequencing (SCS) has impacted many areas of cancer research and improved our understanding of intrat

238 First, cancer risk after antireflux surgery was compared to the

239 2A expression may alter smoking-related lung cancer risk and tissue damage from other inhaled toxins.

240 cycles (LOC) and its components and ovarian cancer risk overall and by histotype.

241 expression could potentially explain breast cancer risk phenotypes.

242 d on creatinine and cystatin C) and ACR with cancer risk using Cox regression models adjusted for pot

243 ing variants, some of which may not increase cancer risk.

244 studies of large curated datasets from human cancer RNA-Seq, where we identify novel putative biomark

245 Advances in cancer screening methods have opened avenues for inciden

246 and nonphysicians are overdue for colorectal cancer screening.

247 Lethal metastatic prostate cancer seems to arise from a single clone in the primary

248 tal gastrectomy and an esophagectomy for GEJ cancer show largely comparable results with regard to lo

249 agnosis had increased risk of recurrence and cancer-specific death.

250 y and CTCF binding sites are associated with cancer-specific gene dysregulation.

251 Information on molecular changes in cancer-specific gene expression facilitates efficient ta

252 We obtained 93 pancreatic cancer specimens (tumor and adjacent nontumor tissues) f

253 Cancer stem cells (CSCs) are a small subpopulation of qu

254 Cancer stem cells (CSCs) have features such as the abili

255 d algorithms could be applied to large-scale cancer studies, such as The Cancer Genome Atlas (TCGA),

256 We evaluated MIXnorm through simulations and cancer studies.

257 The Young Women's Breast Cancer Study is a prospective cohort of women diagnosed

258 rian cancer with a known germline pathogenic cancer susceptibility gene variant should be offered ind

259 to the complex genetic architecture of cross-cancer susceptibility.

260 cally evaluate deleterious DNMs in inherited cancer syndromes.

261 While in its infancy, the field of 'Cancer Systems Immunology' has already influenced our un

262 mors (ATRTs) are challenging pediatric brain cancers that are predominantly associated with inactivat

263 In metastatic cancer, the degree of heterogeneity of the tumor microen

264 their relevance for understanding aging and cancer, the processes that underpin mutational selection

265 myosin receptor kinases (TRKs) are promising cancer therapeutic targets.

266 Antibodies are widely used as cancer therapeutics, but their current use is limited by

267 Thus, ATR is a major target for cancer therapies in homologous recombination-deficient c

268 ) receptor (hY(1)R) are promising targets in cancer therapy due to their high overexpression on cance

269 ogression, and also pose major obstacles for cancer therapy.

270 tential to improve the efficacy of DSF-based cancer therapy.

271 Aberrant Wnt signaling drives a number of cancers through regulation of diverse downstream pathway

272 enabled the cellular architecture of breast cancer tissue to be characterized on the basis of cellul

273 et available to treat triple negative breast cancer (TNBC), which has poor prognosis due to frequent

274 enetic evidence in mouse models for prostate cancer to support the crucial role of Sox2 is missing.

275 Recent advances in new cancer treatment modalities (e.g., gene and immune thera

276 r application of these EFs is as an emerging cancer treatment modality.

277 nd to optimize personalized immunotherapy in cancer treatment.

278 ward loop could potentially be exploited for cancer treatment.

279 humans and proteomic data to classify breast cancer tumours.

280 ing different characteristics of the initial cancer type and aggressiveness.

281 been fully investigated in MDS or any other cancer type.

282 Interestingly, prognostic outcomes of many cancer types have been linked with the expression levels

283 hensive data collection by including 32 TCGA cancer types.

284 trial cancer but had limited effect on other cancer types.

285 s has been observed in treating a variety of cancers using immunotherapy with programmed cell death-1

286 Only the pSCC subtype of tongue cancer was associated with nociceptive behavior.

287 00 on the use of omentoplasty during APR for cancer was undertaken.

288 nown oncoprotein overexpressed in most human cancers, we show that FBXL16 stabilizes C-MYC by antagon

289 Using examples of breast and colorectal cancers, we show that individual cells evolve into tumor

290 Patients with MMR-deficient colorectal cancer were excluded.

291 At the examination level, 181 additional cancers were identified among 1396 total preoperative MR

292 Clinically relevant precursors and early cancers were too small to be detected.Keywords: Genital/

293 urthermore, patients with early-stage breast cancer who experienced cardiovascular events after cance

294 ee blood relatives of a patient with ovarian cancer with a known germline pathogenic cancer susceptib

295 tissue, and in vivo mouse and rat models of cancer with a thermal camera reveals material heterogene

296 ned as the presence of a pathology-confirmed cancer within 12 months.

297 ection is a major cause of liver disease and cancer worldwide.

298 med that 50% of women with invasive cervical cancer would receive appropriate surgery, radiotherapy,

299 MDA-MB-231 breast cancer and FaDu head neck cancer xenografts show different pO(2) responses during

300 o protein Ser/Thr residues, is found on most cancer yet rarely detected in adult normal tissues as re